title: HIV/hepatitis C virus-coinfected patients: is there a better marker for atherogenicity?
authors.forename: Palaniappan
authors.initials: P
authors.lastname: Manickam
authors.forename: Estela
authors.initials: E
authors.lastname: Mogrovejo
authors.forename: Rajesh
authors.initials: R
authors.lastname: Krishnamoorthi
mesh_terms: D044966:Anti-Retroviral Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D002784:Cholesterol / Q000097:blood*; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood*; D008297:Male
chemical_list: D044966:Anti-Retroviral Agents; D008075:Lipoproteins, HDL; D002784:Cholesterol